MedTrace Logo

Multi-Center Study Evaluating the Efficacy of Wobenzym(R)N in Treating Knee Osteoarthritis

NCT00974428 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2016-07-12

No results posted yet for this study

Summary

The objective of this study is to determine the most effective dose of Wobenzym® N versus placebo at reducing pain severity as measured by the WOMAC pain score in subjects with symptomatic knee osteoarthritis (OA) at 6 weeks of treatment.

Conditions

Interventions

DIETARY_SUPPLEMENT

Wobenzym® N

4 tablets TID, 6 weeks

DIETARY_SUPPLEMENT

Placebo

4 tablets TID

Sponsors & Collaborators

  • Atrium Innovations

    lead INDUSTRY

Principal Investigators

  • André Beaulieu, Dr · Centre de Rhymatologie St-Louis

  • Louis Bessette, Dr · Groupe de recherche en rhumatologie et maladies osseuses

  • Morin Frédéric, Dr. · Centre de Recherche Musculo-Squelettique

  • Jean-Pierre Raynauld, Dr · Institut de rhumatologie de Montréal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00974428 on ClinicalTrials.gov